Oxford, UK and Boston, MA — September 8, 2025 — Leads & Copy — Sitryx Therapeutics has appointed Adam Mostafa as Chief Financial Officer, effective today. Mostafa brings over 25 years of experience in biotech and healthcare finance, including raising over $1 billion in institutional capital and securing strategic partnerships. He previously served as CFO for X4 Pharmaceuticals (Nasdaq: XFOR) and Abpro Holdings (Nasdaq: ABP), and currently sits on the Board of Satellos Bioscience (TSX: MSCL) and Precision Biologics and is a Senior Advisor to Cumberland Pharmaceuticals (Nasdaq: CPIX).
Iain Kilty, CEO of Sitryx, expressed his delight at the appointment, citing Mostafa’s expertise and leadership as invaluable for the company’s next phase of growth.
Mostafa stated his enthusiasm for joining Sitryx, praising its innovative clinical pipeline and potential impact on chronic autoimmune and inflammatory diseases.
Sitryx is a clinical-stage biopharmaceutical company focused on developing oral therapies to restore immune balance in autoimmune and inflammatory diseases. Its lead candidate, SYX-5219, is a PKM2 modulator in development for atopic dermatitis.
Sitryx was established in 2018 and has raised $85 million from investors including SV Health Investors, Sofinnova Partners, Oxford Science Enterprises, Longwood Fund, Eli Lilly and Company, and GSK.
Contact: Mary-Jane Elliott, David Daley, +44 (0)20 3709 5700, Sitryx@icrhealthcare.com
Source: Sitryx Therapeutics
